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Abstract
To what extent might the regulation of translation contribute to differentiation programs, or to the molecular pathogenesis
of cancer? Pre-B cells transformed with the viral oncogene v-Abl are suspended in an immortalized, cycling state that
mimics leukemias with a BCR-ABL1 translocation, such as Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic
Leukemia (ALL). Inhibition of the oncogenic Abl kinase with imatinib reverses transformation, allowing progression to the
next stage of B cell development. We employed a genome-wide polysome profiling assay called Gradient Encoding to
investigate the extent and potential contribution of translational regulation to transformation and differentiation in v-Abl-
transformed pre-B cells. Over half of the significantly translationally regulated genes did not change significantly at the level
of mRNA abundance, revealing biology that might have been missed by measuring changes in transcript abundance alone.
We found extensive, gene-specific changes in translation affecting genes with known roles in B cell signaling and
differentiation, cancerous transformation, and cytoskeletal reorganization potentially affecting adhesion. These results
highlight a major role for gene-specific translational regulation in remodeling the gene expression program in
differentiation and malignant transformation.
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Introduction
B cells are the antibody-producing lymphocytes of the immune
system. Ex-vivo transduction of mouse bone marrow with the viral
oncogene v-Abl, a constitutively active version of the cellular c-Abl
protein tyrosine kinase, suspends B cell differentiation in a perma-
nently proliferating state (at the pre-B cell stage) [1,2,3]. This
transformed state is a model for Chronic Myelogenous Leukemia
(CML) and Acute Lymphoblastic Leukemia (ALL), of which 95%
and 30% of cases, respectively, harbor the BCR-ABL1 trans-
location (referred to as Ph
+) that leads to a constitutively active Abl
kinase [4,5,6]. Primary Ph
+ hematopoietic progenitors display
reduced adhesion to the extracellular matrix, and stimulating
adhesion of these cells in culture reduces proliferation, suggesting
that their rampant proliferation is at least in part due to the
inability to activate adhesion molecules [7,8,9,10]. The kinase
activity of both Abl and its oncogenic fusion derivatives can be
inhibited by the small molecule drug, imatinib, which has
dramatically improved prognosis for patients with leukemias
harboring the BCR-ABL1 translocation [11,12]. Unfortunately,
many initially sensitive cancers develop resistance to imatinib,
emphasizing the need for a more complete understanding of the
molecular mechanisms in BCR-ABL1 transformation [13].
Cellstransformedwithv-Ablarearrestedatthepre-Bcellstage,as
areleukemiccellsinPh
+ALLpatients[14,15].Upontreatmentwith
imatinib, v-Abl-transformed cells revert to a quiescent state,
arresting in G1, and eventually undergo apoptosis, as do primary
pro-B cells cultured in the absence of cytokines. RAG (Recombi-
nationActivatingGene)genesandtranscriptionfactorsthatactivate
Immunoglobulin (Ig) Light Chain locus rearrangements are in-
duced,mimickingthetransitionfromlarge,cyclingpre-BIcellsinto
small,restingpre-BIIcells[16].Severaltumor-suppressorgenesare
alsoinducedbyimatinibtreatment(andbyinferencerepressedbyv-
Abl signaling), including Ku80, BRCA1, and Rb. Conversely myc,
N-myc,andLyl1transcriptsdecreaseinresponsetoimatinib(andby
inference are induced by v-Abl) [16]. Thus, this ex vivo system allows
the identification of putative regulators and effectors of pre-B cell
differentiation and/or transformation.
The transcriptional program induced by constitutive Abl kinase
transformation is well studied [16,17,18,19,20] but the gene-
specific translational program of Abl-transformed cells has not
been thoroughly investigated. Translation is extensively altered in
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The constitutively active Abl activates translation through the
MAPK and PI3K/AKT pathways and leads to increased trans-
lation initiation via mTOR phosphorylation of RpS6 and 4E-BP1
[22]. Translation inhibitors have shown promise in battling Ph
+
cancers [23] and the mTOR inhibitor rapamycin works synergis-
tically with imatinib to stop proliferation of CML cell lines in vitro
[24]. While the regulation of translation appears to contribute to
the oncogenic transformation of v-Abl-transduced pre-B cells and
some key proteins have been identified as post-transcriptionally
regulated (namely c-Myc, MDM2, CEBPa, hnRNP E2/Pcbp2
and Cyclin D3) [25,26,27,28], an unbiased, genome-wide survey
of translational regulation in this cancer model has not been
performed. Additionally, as mTOR inhibitors are gaining traction
as therapeutics, it will be important to delineate the genes and
pathways that v-Abl regulates independently of mTOR.
We analyzed the translational regulation of genes in wildtype
Abl-transformed pre-B cells before and after treatment with
imatinib (a v-Abl inhibitor) or rapamycin (an mTOR inhibitor).
We used a streamlined version of traditional polysome profiling on
a genomic scale where mRNAs within sequential fractions of
a linear sucrose gradient were differentially labeled and analyzed
by DNA microarray. This procedure, called Gradient Encoding,
provides an accurate and reproducible ranking of the positions of
mRNAs in the gradient, allowing sensitive detection of changes in
the average number of ribosomes per mRNA, from which we infer
the relative changes in translation rate of each mRNA from one
condition to another [29].
Results
Gradient Encoding Results Are Concordant with
Traditional Polysome Profiling
We used a genome-wide polysome profiling technique, called
Gradient Encoding, to identify genes translationally regulated by v-
Abl transformation, and to define the contribution of mTOR to
this regulation. Lysates harvested before and after 12 hours of
treatment either with 2.5 mM imatinib, a v-Abl kinase inhibitor, or
10 ng/mL (10.9 nM) rapamycin, an mTOR inhibitor, were
fractionated by sedimentation through linear sucrose gradients.
Gradient fractions were ‘‘encoded’’ such that the mRNA from
successive fractions was labeled with increasing ratios of Cy5 to
Cy3. mRNAs derived from fractions in the lighter portion of the
gradient therefore have a lower Cy5 to Cy3 ratio, whereas those
deeper in the gradient have a higher Cy5 to Cy3 ratio. The ratio of
Cy5 to Cy3 for each mRNA therefore reflects its average position
within the gradient (Fig. 1A). We thus ‘‘encoded’’ the sedimenta-
tion rate of each mRNA across the entire gradient. The resulting
ratios were quantitatively measured for each mRNA species by
hybridization to DNA microarrays, and related to the 260 nm
absorbance peaks representing different numbers of ribosomes
bound per mRNA (Fig. 1A, see Materials and Methods). We
assume that changes in the number of ribosomes bound to
a particular transcript in response to treatment represent a change
in the rate of translation of that transcript, provided that 1) the
sedimentation rate is determined by the number of ribosomes
bound to each transcript, 2) initiation is rate-limiting and the
elongation rate is uniform, and 3) the ORF length remains
constant.
We confirmed the Gradient Encoding results for nine selected
genes by high resolution polysome profiling and RT-PCR before
and after imatinib treatment (Fig. 2A, Fig. S1). The analysis for the
two most extreme of these nine genes, Tcf12 (NM_011544) and
Hsp90ab1 (NM_008302), is shown here (Fig. 2A). The relative
change in mRNA abundance was measured simultaneously by
quantitative RT-PCR (qRT-PCR) and is displayed in the insets of
the gradient profiles (Fig. 2A, inset).
We quantitatively analyzed changes in transcript abundance and
translation following imatinib or rapamycin treatment in three
biologicalreplicateexperiments;allthreereplicateexperimentswere
used in subsequent statistical analyses. The change in average
ribosomenumberbetweenconditionsisexpressedastheLog2ofthe
ratioofaverageribsomenumberintreatedversusuntreatedcellsfor
each mRNA. The transcripts with the largest negative values are
therefore those with the greatest apparent reduction in translation
upon imatinib or rapamycin treatment. To quantitatively evaluate
theperformanceoftheencodingmethod,wecalculatedtheexpected
‘‘encoded’’ values, based on the results from qRT-PCR analysis of
individualfractions.TheresultsfromtheindividualgeneqRT-PCR
(qPCR)wereinagreementwiththeresults fromGradient Encoding
(GE) (Pearson r=0.90, Fig. 2B). Western analysis of Hsp90ab1 and
Tcf12, the two most extreme examples of translational regulation
confirmed by qRT-PCR, highlighted in green and red, respectively
(Fig.2B),confirmedthedramaticinductionofTcf12after12hoursof
imatinibtreatmentandshowedmodestreductionofHsp90ab1after
12and18hoursofimatinibtreatment(Fig.2C).However,Hsp90ab1
protein levels were not measurably reduced after 12 or 18 hours of
rapamcyin treatment, despite significant reduction in translation
after 12 hours (the average Log2 ratio was 21.34 for imatinib and
20.86 for rapamycin). This may reflect a difference in protein
stability, which is not measured by our genomic methods, a point
which will be addressed below.
Translational Regulation Contributes Significantly to
Global Reprogramming of Protein Composition in v-Abl
Transformation
We expected a change in translation to result in a corresponding
change in protein production. Proteins with low turnover rates,
however, might show only small changes in overall abundance
even if their synthesis rates changed abruptly after 12 hours of
Figure 1. Schematics for the genomic (gradient encoding) and
proteomic (pSILAC) techniques employed. A) Gradient encoding
relies on separation of mRNAs in a sucrose gradient by virtue of the
number of tethered ribosomes. mRNAs from each fraction are
sequentially labeled with varying red/green ratio and analyzed by
microarray. Each mRNA’s ratio of red/green represents its average
position within the gradient. B) pSILAC involves metabolic labeling of
proteins with either
13C-L-arginine (medium) or
13C-
15N-L-Arginine
(heavy) in place of
12C-
14N-L-arginine only for the duration of drug- or
mock- treatment (in pink or light blue, respectively) such that only
proteins produced during treatment are labeled. The relative protein
production is calculated by quantifying the ratio of treated to untreated
(ie. heavy- to medium-labeled) peptides.
doi:10.1371/journal.pone.0037108.g001
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treatment (Fig. 2C). In order to more accurately measure gene-
specific changes in protein synthesis over the course of drug
treatment we used a pSILAC (pulsed Stable Isotopic Labeling by
Amino acids in Cell culture) method whereby proteins are
metabolically labeled only for the duration of drug treatment
(Fig. 1B) [30]. v-Abl-transformed cells were cultured in standard
‘‘light’’ media and then switched to either ‘‘medium’’ or ‘‘heavy’’
media containing L-arginine with stable isotope-labeled carbon
(
13C-L-arginine) or both carbon and nitrogen (
13C-
15N-L-argi-
nine), respectively, in place of
12C-
14N-L-arginine upon addition of
drug. Protein samples isolated from heavy-labeled, untreated cells
and medium-labeled, imatinib-treated cells were mixed and
,60 mg of this 1:1 mixture of total lysate was subjected to PAGE
(Polyacrylamide Gel Electrophoresis). The ‘‘reverse’’ experiment
was performed comparing heavy-labeled, imatinib-treated cells
and medium-labeled, untreated cells and served as a biological
replicate. Each of the two lanes was cut into 8 slices that were
separately analyzed by mass spectrometry. For each tryptic
peptide that we could confidently identify, we determined the
ratio of the medium to heavy isotope-labeled species, which should
reflect the change in production of the corresponding protein after
12 hours of imatinib treatment. The data from both the ‘‘forward’’
and ‘‘reverse’’ experiments were used to determine the average
ratios of imatinib-treated/untreated protein levels. We restricted
this analysis to proteins for which at least two unique tryptic
peptides were identified. To evaluate the relative contributions of
translational and transcriptional regulation to the observed
changes in protein production, we compared the correlation
between changes in protein production +/2 imatinib and the
corresponding changes in estimated translation (Fig. 3A), tran-
script abundance (Fig. 3B), or the product of these two estimates
(Fig. 3C) for 258 genes (see Table S1).
The observed changes in translation (Spearman r=0.55,
Pearson r=0.55) more accurately predicted changes in protein
production than did changes in mRNA abundance (Spearman
r=0.34, Pearson r=0.27), suggesting that translation indepen-
dently accounts for a large component of the reprogramming of
the cell’s proteome (Fig. 3A-C). We include both Pearson (based
on values) and Spearman (based on rank) correlations here, but
only Spearman correlations are displayed in the figures. The genes
for which we have pSILAC data qualitatively represent the total
population, and are not skewed or clustered into regions of
extreme change in either translation or abundance (Fig. S2).
The genes that made the greatest contribution to the better
correlation of translation than transcription with protein synthesis
rates were, as expected, components of the translation apparatus.
Nevertheless, even when the ribosomal proteins, elongation
factors, and initiation factors were excluded from the pSILAC
dataset (resulting in the removal of data for 25 genes), the
correlations between the changes in synthesis of specific proteins
and either translation (Spearman r=0.47, Pearson r=0.48),
abundance of the corresponding transcripts (Spearman r=0.49,
Pearson r=0.44), or the product of change in mRNA abundance
and translation (Spearman r=0.60, Pearson r=0.53) confirm the
large contribution of translational regulation to reprogramming
the protein composition of the cell.
Figure 2. Changes in translation inferred by gradient encoding
agree with those obtained by qRT-PCR of sucrose gradient
fractions and Western analysis. A) qRT-PCR was performed on an
equal portion of RNA harvested from each fraction from the high-
resolution sucrose gradients performed on lysates from cells either un-
treated (in light blue) or treated with imatinib (in pink). The histogram
of relative mRNA abundance was superimposed over the A260 gradient
trace. The y-axis represents relative absorbance in arbitrary units (AU)
across each gradient, or relative mRNA abundance in each fraction.
Inset) The relative ratio of mRNA abundance of Tcf12 or Hsp90ab1, as
indicated, in the untreated (light blue) or imatinib-treated (pink)
cytoplasmic lysates. (B) Comparison of estimated translation from high-
resolution sucrose gradient fractionation followed by qRT-PCR on the x-
axis (qPCR) to gradient encoding on the y-axis (GE) for 9 genes.
Estimated translation for genes before and after imatinib treatment was
explicitly calculated from the qRT-PCR experiments described in the
Materials and Methods, and expressed as Log2 (treated/untreated).
Values for genes represented by multiple oligos for Gradient Encoding
were averaged. The Pearson correlation (r =0.90) and slope of the trend
line (1.5) are shown. The points representing Tcf12 and Hsp90ab1 are
colored red and green, respectively. C) Western analysis for Tcf12 and
Hsp90ab1, with a-tubulin as a control, was performed on total lysates
after 12 or 18 hours of the specified treatment.
doi:10.1371/journal.pone.0037108.g002
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cannot be inferred from transcript abundance or translation rates,
could play an important role, genome-wide quantitation of both
changes in translation and changes in mRNA abundance greatly
improves our ability to infer the global reprogramming of the cells
proteome by enabling quantitative analysis of more than ten times
as many genes as can be evaluated by current proteomic methods.
A Major Role for mTOR in Reprogramming of Gene
Expression by v-Abl
Concerted, large-scale activation of translation is a hallmark of
the mTOR pathway [31,32]. BCR-ABL1 induces phosphorylation
of 4E-BP1 and S6K via mTOR through activation of both the
PI3K and MAPK pathways [24]. Because the genes encoding
components of the ribosome and translation complex subunits
comprise a substantial fraction of the ribosome-associated mRNAs
in dividing cells, the decreased translation of these genes may
explain much of the global redistribution of mRNAs from
polysomes to monosomes, reflected in the 260 nm trace of the
polysome profile following imatinib treatment (Fig. 4A, and [22]).
Qualitatively, rapamycin treatment produced a less prominent
shift in ribosomes towards monosomes than did imatinib (Fig. 4A).
Rapamycin sterically hinders formation of mTORC1, but not
mTORC2 [33] and mTORC1 inactivation can activate
mTORC2, due to loss of a negative feedback from mTORC1
on the mTORC2 complex [34]. However, chronic exposure to
rapamycin has been shown to also inhibit mTORC2 [35]. We
tested the degree of mTORC1 and mTORC2 inhibition by the
loss of phosphorylation of Ribosomal protein S6 (RpS6) (an
mTORC1 target) or AKT-Ser473 (an mTORC2 target) (Fig. 4B).
No augmentation of mTORC2 activation by rapamycin was
observed; phosphorylation of RpS6 and AKT-Ser473 was reduced
to a comparable extent by either imatinib or rapamycin, at the
concentrations and duration of drug used here.
mTOR canonically induces translation of genes harboring
a5 9TOP sequence [36]. The requirement of this signal for
mTOR-dependent translational regulation, however, is not
stringent, and cell-type-dependent responses to mTOR inhibition
are common [37]. Therefore, we compared the translational
reprogramming after imatinib to that after rapamycin treatment in
order to determine the contribution of mTOR to the translational
re-programming of v-Abl. Figure 5A shows genes statistically
significantly activated (in red) by imatinib (by inference repressed
by v-Abl) and repressed (in green) by imatinib (by inference
activated by v-Abl) in scatterplots relating changes in translation to
mRNA abundance (Fig. 5A). Of the 10507 unique genes for which
we had data in three replicate experiments, 175 unique genes were
deemed significantly activated by imatinib (10% FDR (false
discovery rate) cut off, using significance analysis of microarrays
(SAM)), and 591 genes were repressed (10% FDR cut off, SAM).
Despite equal dephosphorylation of RpS6 and AKT-Ser473, the
range of change in translation affected by rapamycin was smaller
than that following imatinib treatment. None of the 10688 unique
genes for which we acquired rapamycin data in triplicate were
translationally induced and 192 unique genes were repressed at
a 10% FDR threshold (Fig. 5B).
Despite the difference in magnitude, the pattern of changes in
translation after imatinib treatment correlated well with changes
following rapamycin treatment (Pearson r=0.65, Fig. 5C),
suggesting that mTOR activation could in principle account for
much of v-Abl induced translational induction. In addition,
rapamycin-induced changes in mRNA abundance correlated
quite well with those induced by imatinib (Pearson r=0.47,
Fig. 5D) suggesting that mTOR activation could also (perhaps
indirectly) account for a substantial component of the change in
mRNA abundance in these cells. However, there are isolated cases
where imatinib and rapamycin caused discordant effects on the
translation of specific genes, which will be discussed below.
Figure 3. Changes in translation (inferred from gradient
encoding) predict changes in protein abundance. A) Change in
Translation versus Change in pSILAC. A scatter plot of the change in
protein abundance as measured by pSILAC vs. the change in translation
by Gradient Encoding, each expressed as the Log2 (treated/untreated).
Trend lines and r values for the Spearman correlations between the two
datasets are shown in black. B) Change in mRNA Abundance versus
Change in pSILAC. As in ‘‘A’’, but the x-axis is the change in mRNA
abundance. C) Product of the Change in the mRNA Abundance and
Change in Translation versus Change in pSILAC. As in ‘‘A’’, but the x-axis
is the Log2 (treated/untreated translation x treated/untreated mRNA
abundance). Abund. = Abundance, Trans. = Translation.
doi:10.1371/journal.pone.0037108.g003
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Following Abl Inhibition
Imatinib treatment induced gene-specific changes in mRNA
abundance that generally paralleled the corresponding changes in
translation (Spearman r=0.31, Fig. 5A). Despite this overall
correlation, 109 of the 175 genes with significant increases in
translation and 390 of the 591 genes with significantly reduced
translation showed changes in mRNA abundance that were within
one standard deviation (SD) of the mean for all detectable mRNAs
(Fig. 5A, purple lines represent 1 SD). Translational regulation
thus appeared to be the principal mode of regulation for more
than half of the ,770 genes either activated or repressed by v-Abl
(see Tables S2 and S3, respectively).
Genes with functional roles in translation were highly over-
represented (p,10
232, GO term enrichment) among the genes
whose ribosome density decreased upon addition of imatinib, very
likely reflecting the activation of mTOR by v-Abl. Genes encoding
mitochondrial proteins (p,10
211, GO term enrichment) were also
over represented in this group, suggesting that v-Abl activity can
promote translation of genes involved in aerobic respiration. In
general, the translational response to rapamycin was similar but
weaker than that to imatinib for both mitochondrial and
translation apparatus genes (Tables S3 and S4). Comparing
average changes in translation across experiments confirms the
general concordance between rapamycin and imatinib trans-
lational regulation for these subsets with one notable exception;
C1qbp (Complement 1q-binding protein) is translationally in-
duced by imatinib treatment while rapamycin has the opposite
effect (Fig. 6A, Fig. S3A). C1qbp is a mitochondrial/cell surface
protein implicated in promoting tumorigenesis [38,39].
Genes involved in antigen processing and presentation were also
significantly over-represented among the transcripts whose trans-
lation was inhibited by imatinib (p,0.025, KEGG pathways,
Tables S2 and S4). A similar pattern in response to rapamycin
treatment (Fig. S3A) suggests that the inhibition of MHCI antigen
presentation canonically seen upon rapamycin treatment is due
not only to reduced translation in general, but also to specific
translational regulation of proteins participating in the antigen
presentation pathway, such as Tap1, Erap1/Arts and constituents
of the proteasome.
Three genes activated by v-Abl caught our attention due to their
involvement in leukemia and cancer: Hmga1 (NM_016660),
hnRNP A1 (NM_010447), and Hsp90ab1. Both hnRNP A1 and
Hsp90ab1 have previously been reported to play important roles
in BCR-ABL1-mediated leukemogenesis [40,41,42]. Although
HMGA1 is a known oncogene, to our knowledge, it has not
previously been implicated in v-Abl–mediated transformation. All
three of these genes displayed almost complete translational arrest
upon imatinib treatment (Fig. 2A, Fig. S1). The abundance of
these mRNAs also decreased, but only by roughly 1.5 to 2 fold
(Fig. 2A, Fig. S1, Fig. S3B). These data suggest that v-Abl activates
the expression of these genes predominantly by promoting their
translation. Translation of hnRNP A1 and Hsp90ab1 was also
significantly translationally repressed by rapamycin treatment, but
the change in Hmga1 translation upon rapamycin treatment was
not significant by SAM (local FDR 88%, Fig. 6A, Fig. S3A), and
was less than one standard deviation from the mean, suggesting
that mTOR activation is responsible at least in part for the v-Abl
dependent translational induction of Hsp90ab1 and hnRNP A1,
but not significantly for translational induction of Hmga1 (Fig. 6A).
The abundance of all three transcripts changed only slightly in
response to treatment (Fig. 6C, Table S3B, Fig. S1).
Although the predominant effect of v-Abl inhibition was to
decrease translation, ,160 genes were translationally activated
upon imatinib treatment with a striking enrichment for genes
encoding nuclear proteins (p,10
211, GO term enrichment) and
proteins involved in cytoskeletal reorganization, particularly
integrin activation.
Nuclear proteins translationally repressed by v-Abl included
transcription factors implicated in repressing the IgH locus (Ezh2
(NM_007971), Cux1/Cutl1 (NM_009986), Bach2 (NM_007521),
perhaps with MafG (NM_010756)) [43,44,45,46,47], activating
RAG and/or promoting B cell differentiation (Foxp1
(NM_053202), Lef1 (NM_010703), Bcl6 (NM_009744))
[48,49,50,51], and tumor suppression (Ssbp2 (NM_024186),
Figure 4. The translational response of v-Abl-transformed pre-
B cells to imatinib (2.5 mM for 12 hours) or rapamycin
treatment (10.9 nM for 12 hours) or no treatment. A) OD260
traces (arbitrary units, AU) of typical sucrose gradients (top of gradient
is on the left) either untreated (Untreated), treated with 2.5 mM imatinib
for 12 hours (Imatinib), or with 10 ng/mL rapamycin for 12 hours
(Rapamycin). Alternating blue and white columns represent fractions. B)
The same cytoplasmic lysates treated with imatinib (Imat.), rapamycin
(Rap.), or untreated (Un.) that were used for gradient encoding were
subjected to Western analysis using the antibodies indicated. Results
are representative of three replicate experiments.
doi:10.1371/journal.pone.0037108.g004
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role in B cell development but could putatively enhance klocus
activation due to their ability to interfere with Id protein inhibition
of E2A products (Mef2a (NM_013597), Tcf12 (NM_011544),
Zfp238 (NM_013915)) (see Table S2 for a complete list).
Discordant yet significant regulation of multiple genes with
shared functional roles was observed for genes involved in actin
cytoskeleton reorganization and the phosphoinositide 3-kinase
(PI3K) pathway, both of which were enriched in the v-Abl-
repressed gene set (p,0.037, KEGG pathways, Table S4). The
PI3K pathway (induced downstream of the pre-BCR) was over-
represented in the v-Abl-repressed gene set; they included Itpkb
(Inositol 1,4,5-trisphosphate 3-kinase B) (NM_001081175), Dgk
d (DAG kinase d) (NM_177646), Pik3ca (PI3K catalytic subunit
110a) (NM_008839), and Calm1 (Calmodulin 1) (NM_009790),
although a number of molecules in convergent pathways were
translationally induced by v-Abl, including PLCc2 (NM_172285),
Rac2 (NM_009008), Nek3 (NM_011848), and AI586015/Stap1/
BRDG1 (BCR Downstream Signaling 1) (NM_019992) [54,55,56].
The set of genes repressed by v-Abl was enriched for involvment in
actin cytoskeleton reorganization, represented by Ppp1cb
(NM_172707), Cyfip2/Pir121 (NM_133769), Iqgap1
(NM_016721), Itga4 (NM_010576), Pik3ca (NM_008839),
Wasf2/WAVE2 (NM_153423), Rassf5/RapL (NM_018750). Ad-
ditional v-Abl-repressed genes potentially involved in cytoskeletal
reorganization but not included in the KEGG annotations include
Stk4/Mst1 (NM_021420) [57], Ptpn12 (NM_011203) [58],
Pacsin2 (NM_011862) [59], Triobp (NM_138579) [60], and
Sipa1l1 (NM_172579) [61] (Fig. 7). A few regulators of actin
reorganization, Was/Wasp (NM_009515) [57], Coro1A (Coronin-
1) (NM_009898) [57], D10Wsu52e/FAAP (NM_145422) [62], and
Pstpip1 (NM_011193) [58], were translationally induced by v-Abl.
The significant repression of Cyfip2/Pir121, Wasf2/WAVE2,
Rassf5/RapL, Stk4/Mst1 and Itga4 by v-Abl is notable due to
their concordant involvement in TCR-mediated integrin activa-
tion [57]. Conversely translation of another molecule important
for hematopoietic cell adhesion, Cd44 (NM_009851), is induced
by v-Abl [63]. The discordant regulation of functionally related
genes demonstrates the gene-specific nature of v-Abl’s trans-
lational regulation, and suggests its involvement in re-wiring
pathways affecting BCR signaling and adhesion.
In contrast to genes encoding mitochondrial proteins and the
translation apparatus, those involved in cytoskeletal reorganization,
BCR signaling, and transcription factors had morevaried responses
to rapamycin (Fig. 6A-B and Fig. S3A). None of the genes
translationally activated by imatinib treatment were significantly
induced by rapamycin treatment at the 10% FDR cutoff. The gene
whose translation was most differentially regulated in response to
imatinib was Cyfip2, a gene whose overexpression single-handedly
increases TCR-mediated adhesion [64](Fig. 6B).
Using the same significance criteria (10% FDR, SAM), more
than twice as many genes showed significant changes at the level of
Figure 5. Changes induced by imatinib correlate with changes induced by rapamycin. A) Imatinib Change in mRNA Abundance versus
Change in Translation. Red points represent the genes that were deemed statistically significantly translationally repressed by v-Abl (and activated by
imatinib) (FDR ,10%, SAM). In green are those statistically significantly translationally activated by v-Abl (and repressed by imatinib) (FDR ,10%).
Purple vertical lines define one standard deviation from the mean change in mRNA abundance and the trendline is shown in black. Spearman
correlations are given. B) The Rapamycin Change in Abundance versus Change in Translation. As in A) but for rapamycin. C) Change in Translation for
Imatinib versus Rapamycin. The trendline is in black and Pearson correlation is given. D) Change in mRNA Abundance for Imatinib versus Rapamycin.
The Pearson correlation is given. All values are expressed as Log2 (treated/untreated). Imat. = imatinib, Rap. = rapamycin, Abund. = abundance.
doi:10.1371/journal.pone.0037108.g005
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limited overlap between these two groups. Fewer than half of the
translationally regulated genes distinguished by GO term or
KEGG pathway analysis discussed above also significantly
changed at the level of mRNA abundance, stressing the large
amount of information missed by only considering changes in
mRNA abundance (Fig. 6C-D, Fig. S3B). Over half of the
transcription factors with significant translational changes did not
significantly change at the level of mRNA abundance. Moreover,
GO term and KEGG pathway analysis failed to identify antigen
processing, lysosome constituents, the phosphatidylinositol signal-
ing system or regulation of actin cytoskeleton as enriched
categories using genes significantly changing only at the level of
mRNA abundance (using either the same number of genes as used
for translation, or the same 10% FDR cutoff, SAM). A table of all
combined data is provided (Data S1).
v-Abl orchestrates a dynamic, gene-specific program of post-
transcriptional regulation of the basic cell machinery necessary for
rapid proliferation, increasing expression of oncogenes, as well as
re-wiring signaling pathways that govern cell fate decisions (Fig. 7).
The selective translational activation or repression of diverse genes
in response to imatinib treatment suggests that extensive
reprogramming of translation is likely to play an important part
in the ability of activated Abl to arrest B cell differentiation and
Figure 6. Heatmaps depicting changes in translation upon
imatinib and rapamycin treatment for genes either significant-
ly translationally activated (A,C) or repressed (B,D) by v-Abl.
Normalized average change (median=0, SD=1) was used to display
changes in translation upon treatment with imatinib versus rapamycin
as indicated (A,B) or changes in translation versus changes in mRNA
abundance upon treatment with imatinib (C,D). Heatmaps are ordered
by increasing change in translation upon rapamycin treatment (A,B) or
by increasing change in mRNA abundance upon imatinib treatment
(C,D). In cases where multiple oligos represent a gene, the oligo with
the biggest change in translation upon imatinib treatment was used.
Genes that were regulated translationally by imatinib but not
rapamycin (A,B) or regulated translationally but not at the level of
mRNA abundance by imatinib treatment (C,D) are highlighted in yellow
(10% FDR cutoff, SAM). (SD, standard deviation).
doi:10.1371/journal.pone.0037108.g006
Figure 7. A summary of the contribution of v-Abl translational
re-programming to differentiation arrest and leukemogensis.
doi:10.1371/journal.pone.0037108.g007
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Discussion
An Independent Role for Translational Reprogramming
We found that translational regulation plays a major role in v-
Abl-mediated reprogramming of the proteome during B cell
differentiation and transformation. We observed significant trans-
lational activation or repression of almost 800 genes in response to
imatinib treatment. For more than half of these the corresponding
change in mRNA abundance was less than 1SD from the mean,
suggesting that translation plays an important, independent role in
v-Abl-mediated regulation of gene expression in this system.
We compared the observed changes in translation to changes in
protein production using pSILAC (Fig. 1B) [30], where newly
synthesized proteins are metabolically labeled only for the course
of drug (or mock) treatment. We found extensive imatinib-sensitive
reprogramming of translation that correlated with changes in
protein production following imatinib treatment, including many
cases where changes in mRNA abundance did not, suggesting that
for many genes, the dominant mode by which gene expression is
reprogrammed in response to Abl-activation is post-transcription-
al. While examples of translation regulation in the absense of a shift
of the corresponding mRNA in the gradient, or stalled complexes,
exist [65,66], the good correlation between changes in protein
production (measured by pSILAC) and the changes predicted
from changes in translation rates lends credence to our inference
of translation rates from the sedimentation of mRNAs through the
gradient. While our method does not provide specific information
about ribosome position on the mRNA, an advantage of the
recently-reported footprinting method [67], Gradient Encoding is
less experimentally challenging and less expensive, and it should
provide better quantification of less abundant mRNAs, such as
those encoding transcription factors, for which the sparse coverage
and biased sampling of sequence-based methods might be limiting.
The ability to infer changes in the proteome from purely genomic
data greatly increases the number of proteins whose regulation can
be quantitatively evaluated including proteins that are currently
difficult or impossible to measure directly by mass spectrometry or
immunoassays.
A handful of genes have been previously shown to be post-
transcriptionally regulated by BCR-ABL1. In agreement with
previous results c-Myc was induced by v-Abl both transcriptionally
and translationally, [16,25]. Also in agreement with previous
observations, hnRNP E2/Pcpb2 was significantly translationally
repressed by imatinib, but the target of its post-transcriptional
regulation, C/EBPa, is not expressed in this pre-B cell line [28].
Discrepancies between our data and previous reports of trans-
lational effects of BCR-ABL1 in myeloid cells, such as translational
(and transcriptional) induction of Cyclin D2, rather than D3 [27],
and the absence of v-Abl-mediated translational induction of
MDM2 in our murine cell line (where we observed modest v-Abl-
mediated repression of MDM2 translation) [26], are likely to
reflect cell-type specific features of this translational program.
Indeed, genes downstream of mTOR translational regulation are
known to be cell-type specific [37] most likely due to the presence
of cell-type specific trans-acting factors mediating mTOR-induced
translational regulation.
mTOR Activation Explains Much but not all of v-Abl-
mediated Translational Reprogramming
mTOR inhibitors have gained attention for their efficacy in
combating Ph+ leukemias [23]. Understanding mTOR-dependent
and -independent aspects of v-Abl-mediated transformation
should indicate pathways not effectively targeted by mTOR
inhibitors. We were able to assess the contribution of the mTOR
pathway to v-Abl regulation of translation by comparing imatinib-
to rapamycin-treated v-Abl-transformed cells. Rapamycin and
imatinib inhibited mTORC1 activation equally well as measured
by RpS6 phosphorylation (Fig. 4B). Inhibition of mTOR by
rapamycin may not always be qualitatively or quantitatively
complete. For example inhibition of mTOR by rapamycin can
relieve S6 Kinase-mediated inhibition of PI3K [34], a negative
feedback mechanism in the mTOR pathway, which can lead to
activation of mTORC2. Although in our experiments mTORC2
activation, as measured by phospho-Ser-473 AKT, was not
increased by rapamycin treatment, we cannot exclude the
possibility that other mechanisms make rapamycin less efficient
than imatinib in inhibiting the mTOR pathway.
Although much of the v-Abl-mediated translational activation
appears to be through mTOR, individual genes translationally
regulated by v-Abl vary in their dependence on mTOR (Fig. 6A-
B, Fig. S3A). mTOR appeared to be responsible for the increased
translation of many components of the translation apparatus as
well as a large number of mitochondrial proteins. In Jurkat cells,
disruption of mTOR-raptor interactions critical for functional
mTORC1 (the rapamycin-sensitive mTOR complex) have been
correlated with a lower mitochondrial membrane potential [68].
BCR-ABL1-positive cells produce ROS (reactive oxygen species)
due to PI3K/mTOR-mediated over-activation of electron trans-
port [69]. Our results suggest the possibility that v-Abl/mTOR-
mediated translational activation of the enzymes involved in
mitochondrial ATP production contributes to these responses.
The mitochondria-associated gene most differentially translation-
ally regulated by imatinib and rapamycin, C1qbp (NM_007573)
(imatinib significantly suppresses while rapamycin slightly in-
creases its translation), has been implicated in suppressing
mitochondrial-mediated cell death, thus preventing apoptosis
despite ROS overproduction [39](Fig. 6A, Fig. S3A). Pathways
involved in such ‘‘non-oncogene dependencies’’ are now recog-
nized as possible cancer-specific therapeutic targets [70,71]. Gstp1
(Glutathione-S-transferase pi 1), previously implicated to play such
a role, is similarly translationally activated by v-Abl and
significantly repressed by imatinib but not rapamycin treatment
(FDR =85%) [70]. Thus, our data suggest that there is an
rapamycin-insensitive component to v-Abl’s translational activa-
tion of these ROS-controlling genes. Similar cases of predomi-
nantly rapamycin-insensitive v-Abl regulation will be discussed
below.
Oncogenes are Translationally Induced by v-Abl
We identified three genes involved in leukemogenesis whose
translation was markedly repressed by imatinib; Hmga1, hnRNP
A1, and Hsp90ab1. HMGA1 is a known oncogene with no
previously identified role in Abl signaling. hnRNP A1 influences
cap-dependent translation [72] and plays roles in RNA splicing
and nuclear export [73] and its nucleo-cytoplasmic shuttling
activity may be necessary for BCR-ABL1-induced leukemogenesis;
indeed, levels of this protein increase in patients in CML blast
crisis (the terminal phase of the disease) [40]. Hsp90ab1 translation
was repressed and protein levels were diminished following
imatinib treatment (Fig. 2A, 2C). Inhibiting Hsp90ab1 with
geldanamycin and 17-allylaminogeldanamycin (17-AAG) leads to
BCR-ABL1 degradation and inhibited cell growth in BCR-ABL1
expressing cells [74]. Its repression in response to imatinib
treatment (and by inference activation by v-Abl) suggests that it
might participate in a positive feedback loop that maintains
activation of this pathway. Translation of these three genes was
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at all for Hmga1 (FDR .87%, Fig. 6A), suggesting that they are
regulated in part through the mTOR pathway.
v-Abl Represses Translation of Differentiation-Promoting
Transcription Factors
Transcription factors are highly enriched (p,0.0028, Genetrail,
GO term enrichment, see Table S4 for a complete list) among the
genes translationally-repressed by v-Abl; many of these have been
previously implicated in regulating B cell development, including
Foxp1, Lef1, Bcl6, Bach2, and Cux1. Foxp1 and Lef1 are required
for proper RAG2 expression and B cell development [48,75,76].
Bcl6 regulates the pro- to pre-B cell transition by protecting pre-B
cells undergoing Light Chain rearrangement from DNA damage-
induced apoptosis and also prevents plasma cell differentiation in
concert with Bach2 [50,77,78]. In addition, Bach2 represses
a reporter construct containing the IgH enhancer in partnership
with a small, as yet unidentified, Maf protein [47]. The coordinate
translational activation of MafG suggests it as a prime candidate
for this role. Cux1, which affects double positive (DP) T cell
development by repressing the TCRb enhancer, similarly binds
regions throughout the IgH V (VH) genes and represses the IgH
intronic enhancer in vitro [44,45,79]. The concomitant trans-
lational induction of proteins implicated in repressing the IgH
locus (Cux1, Bach2, and possibly MafG) upon induction of pre-B
cell differentiation could implicate their involvement in allelic
exclusion.
Light Chain (ie. k locus) activation is sensitive to the dosage of
basic Helix-loop-helix (bHLH) E2A proteins [80] which are
inhibited by binding to Id proteins [81,82]. Translational in-
duction of the bHLH proteins Mef2a and Tcf12 (whose protein is
dramatically induced, Fig. 2C) might enable them to compete with
the E2A proteins for binding to the inhibitory Id proteins, thus
promoting k locus activation. The overlapping and coordinated
roles of these transcription factors in B cell development are
mirrored in their synchronized translational activation upon
imatinib treatment.
v-Abl Regulates Translation of Molecules in pre-BCR
Signaling Pathways
pre-B cells require signals from the pre-BCR in order to
proliferate, and BCR-ABL1-positive pre-B cells bypass this
requirement by mimicking some aspects of pre-BCR signaling
[83]. However, the ability to signal downstream of the pre-BCR is
selected against in Ph
+ leukemias, and BCR-ABL1-mediated
repression of pre-BCR-induced Ca
2+ signaling has been described
in Ph
+ B-ALL patients, and in a mouse ALL model [14,15,83].
Additionally, v-Abl-transformed pre-B cells resemble pre-B cells
that have not received the pre-BCR signal in that they continue to
rearrange Heavy Chain loci in the presence of a successfully
rearranged Heavy Chain, thus failing to induce allelic exclusion,
and the Light Chain loci are inactive [16,84]. Treatment of v-Abl
transformed pre-B cells with imatinib has been previously shown
to mimic pre-BCR signaling, with activation of the RAG proteins
and subsequent Light Chain rearrangements [16]. Thus the
constitutively active Abl mimicks the proliferative signals induced
by the pre-BCR, but prevents the calcium flux and differentiation
downstream of pre-BCR signaling. Our data show that a number
of genes that influence these pathways are translationally regulated
by v-Abl, some independent of changes in mRNA abundance and
some with no measurable contribution from mTOR (Fig. 6).
PI3K signaling through a Tec kinase/Rac2/Vav pathway is
responsible for the pre-BCR-induced calcium flux described above
[85]. Our results show that v-Abl translationally represses
constituents of the phosphatidylinositol signaling pathway
(p,0.037, KEGG pathways), as evidenced by the imatinib-
dependent translational activation of Pik3ca- the catalytic subunit
of PI3K, Calm1, Itpkb, and Dgkd. Conversely, a set of genes likely
to positively regulate the phosphatidylinositol signaling pathway
were translationally repressed upon imatinib treatment: PLCc2,
Rac2, AI586015/Stap1/BRDG1 (BCR Downstream Signaling 1)
and Nek3 [54,55,56]. Nek3, while not directly implicated in pre-B
cell signaling, phosphorylates Vav1 and 2 in a breast cancer line
[55,56]. Stap1 provides a positive feedback loop for Tec kinases
downstream of BCR signaling [54]. The transforming ability of
the constitutively active Abl kinase is dependent on activation of
the PI3K pathway, Rac2 and Vav. [86,87,88,89,90,91]. Indeed
a dominant negative Rac prevents ERK activation and induction
of proliferation by v-Abl [88,89].
The signal from the pre-BCR normally promotes either
differentiation or cell death [92]. The majority of the pre-B cells
from the Ph
+ ALL mouse model mentioned above lacked
a functional pre-BCR, and restoration of the pre-BCR signal
induced calcium flux and cell death [14,15]. Perhaps this
translational re-programming contributes to v-Abl’s ability to
bypass the necessity of a pre-BCR signal for proliferation (by
activating the PLCc2/Rac2/Vav pathway), while preventing
a concerted calcium flux that would either result in cell death or
differentiation (by repressing constituents of the phosphatidylino-
sitol pathway). Rapamycin caused changes in translation of Rac2,
Stap1, and Nek3 that were not significant by SAM and no changes
at the level of abundance were observed upon imatinib treatment
(the lowest local FDR for either change in rapamycin-induced
translation or imatinib-induced changes in transcript abundance
being 78%).
v-Abl Represses Translation of Adhesion-Activating
Molecules
pre-BCR-mediated calcium flux induces adhesion via integrin
activation [85]. The Abl protein interacts with a number of
cytoskeletal proteins and is known to alter protein interactions at
sites of adhesion [93]. Our data provide evidence that Abl
influences cytoskeletal re-organization at the level of translational
regulation as well. v-Abl translationally represses five key proteins
involved in TCR-mediated integrin activation including Wasf2/
WAVE2, Stk4/Mst1, Rassf5/RapL and Cyfip2, as well as
a subunit of one of the integrins implicated in Ph
+ CML adhesion,
Itga4 [10,57]. Another cytoskeletal protein translationally re-
pressed by v-Abl, IQGAP1, both co-localizes at sites of adhesion in
NK-like cells and co-immunoprecipitates with Rac2 and RACK1
(receptor for activated C kinase) and is thought to target calcium/
calmodulin signaling to the cytoskeleton [94,95,96]. Recently
mTOR signaling has been implicated in regulating the translation
of factors important for metastasis in prostate cancer [97]
suggesting that translational control of adhesion and migration
may be a common theme in cancer pathogenesis.
Reduced adhesion to bone marrow stroma and early egress
from the bone marrow are hallmarks of Ph+ CML hematopoietic
progenitors; translational repression of integrin-activation mole-
cules could contribute to this phenotype. However, reports of
BCR-ABL1 expression increasing adhesion in the Ba/F3 pro-B
cell line [98,99] raise the alternative possibility that the apparent
reduced translation observed when v-Abl is active could be a result
of localized translation necessary for activation of these adhesion
molecules, since localized translation inherently requires the
repression of translation of the mRNAs while in transit, prior to
proper localization.
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of mRNA abundance (lowest FDR being 27%). The change in
translation of Cyfip2, Rassf5/RapL and Stk4/Mst1 upon
rapamycin treatment was not significant by SAM (the lowest local
FDR being 61%). In addition Cyfip2, which is alone sufficient for
increased TCR-mediated adhesion, is induced by imatinib both
transcriptionally and translationally yet repressed at both levels by
rapamycin (Table S2) [57]. These data suggest that rapamycin and
imatinib might have different effects on the adhesion properties of
Ph
+ cells.
Conclusions
We have uncovered major changes in post-transcriptional
regulation of genes with critical roles in transformation or
differentiation, and identified additional genes with potential roles
in these processes based on specific changes in their translational
regulation. Gene-specific changes in net protein synthesis were
better predicted by the measured changes in translation than by
changes in mRNA abundance for ,260 proteins quantitatively
profiled by pulsed SILAC-mass spectroscopy. We propose that v-
Abl-mediated gene-specific translational regulation contributes to
the transformed phenotype and adhesion defects of Ph
+ cells from
CML patients, as well as the differentiation arrest of pre-B cells
observed in v-Abl transformed bone marrow and Ph
+ ALL. These
results highlight the critical role of gene-specific translational
regulation in shaping the proteomic landscape in both cancerous
transformation and differentiation.
Materials and Methods
Cell Lines and Cell Culture
Abl-transformed cells (E2A
+/+ [80]) were maintained in RPMI
1640 with Glutamine added (Gibco, cat.# 22400-121) supple-
mented with 5%, heat-inactivated FCS (HyClone), 1x Pen/Strep
(Gibco cat.# 15140122) and 50 mM b-mercaptoethanol. Cells
were incubated at 37uC with 5% CO2. The kinase inhibitor
imatinib (imatinib mesylate, aka. STI-57I or Gleevec) (Novartis)
was prepared as a 10 mM stock solution in EtOH, sterile filtered,
and stored in aliquots at –20uC and used at a concentration of
2.5 mM. The mTOR inhibitor rapamycin was prepared as
a 5 mg/mL stock in EtOH and used at a final concentration of
10 ng/mL. For SILAC analysis, v-Abl transformed pre-B cells
were grown in light media as per the SILAC protein quantitation
kit-RPMI 1640 (Pierce Thermo Scientific cat.# 89982). Cells were
washed in SILAC media without L-arginine twice, and then
resuspended in either media containing 50 mg/500 mL
13C-L-
arginine (medium) or 50 mg/500 mL
13C-
15N-L-Arginine (heavy)
in place of
12C-
14N-L-arginine and immediately either mock or
imatinib-treated. Both medium and heavy media were supple-
mented with 115 mg/L proline to limit metabolic conversion of
arginine to proline [100].
Preparation of Cell Extracts for Translation Profiling
For translation experiments, ,60–100 million v-Abl trans-
formed pre-B cells, either treated or untreated with imatinib or
rapamycin (see Cell Culture) were harvested by resuspension in
ice-cold buffer A (20 mM Tris pH 8.0, 140 mM KCl, 5 mM
MgCl2, 0.1 mg/ml cycloheximide (Calbiochem Cat.# 239764).
After the second wash, cells were resuspended in lysis buffer which
was buffer A containing 0.22 mg/ml of heparin, 16 protease
inhibitor cocktail (Pierce Cat.# 78437), 100 U/ml SUPERASin
(Ambion Cat.# AM2696), and 0.5 mM DTT, 0.1% Brij 58
(Sigma Aldrich Cat.# P5884-100G) and 0.1% sodium deoxycho-
late (Sigma Aldrich Cat.# D6750-100G). Cells were kept on ice
for 15 min with intermittent inversion and then spun at 9,500 rpm
in a microcentrifuge for 5 min at 4uC yielding ,6–10 A260 units.
Supernatant was collected, flash frozen in liquid nitrogen, and
stored at 280uC until use.
Western Analysis
For Tcf12 and Hsp90ab1 Westerns, equal numbers of cells were
extracted with RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS), spun at
maximum speed for 5 min., and an equal volume of supernatant
was run on SDS-PAGE, transferred, and blotted with anti-Tcf12
(Protein Tech group cat.# 14419-1-AP) or anti-Hsp90beta (Stress
Marq cat.# SMC-136), respectively. For anti-pan and anti-
phospho- AKT or RpS6, equal A260 units of the same
cytoplasmic cell extracts used for gradient encoding were subjected
to PAGE, transferred, and blotted with anti-phospho RpS6 (Cell
Signaling cat.# 4838), anti-pan RpS6 (Cell Signaling cat.# 2317),
anti phospho-Ser473-AKT (Cell Signaling, cat.# 4058S), or anti-
pan-AKT (Cell Signaling cat.# 9272). Anti-a tubulin (SIGMA,
cat.# T6189) was used as a control for both assays. All antibodies
were used as per vendor instructions.
Sucrose Gradient Preparation
Sucrose gradients were prepared using the Gradient Master
(Biocomp) according to the manufacturer’s suggestions. Five
percent and 60% (w/v) sucrose solutions were prepared by
dissolving sucrose in Gradient Buffer (20 mM Tris-HCl pH 8.0,
140 mM KCl, 5 mM MgCl2, 0.5 mM DTT, 0.1 mg/ml cyclo-
heximide) at room temperature. The 60% solution was dispensed
into an SW41 ultracentrifuge tube through a cannula underneath
the 5% solution. Using an 11-step program (Biocomp, SW41
SHORT SUCR 5–50 11), the two solutions were mixed on the
Gradient Master to form a linear gradient. After preparation,
gradients were chilled for 30 min at 4uC.
Sucrose Gradient Velocity Sedimentation
Immediately before centrifugation, ,3.75 A260 units of lysate
was transferred to the surface of the gradient after an equal volume
was removed from the top of the gradient. Gradients were
centrifuged at 41,000 rpm (RCFave =207,000) for 70 min at 4uC
using a SW41 rotor and then stored at 4uC until fractionation. The
Gradient Station (Biocomp) trumpet tip was lowered into the
ultracentrifuge tube at a rate of 0.17 mm per second. Fractions (12
drops each, ,550 ml) were collected into a 96-well plate contain-
ing 600 ml of lysis solution (Invitrogen cat.#, with b -mercap-
toethanol added) using a fraction collector (Foxy Jr.). The
absorbance of the gradient at 260 nm was measured during
fractionation using a UV6 system (Teledyne-Isco).
Gradient Encoding
Gradient Encoding was performed as described previously [29]
with changes specified below. Briefly, in vitro transcribed mRNAs
with 25 nt polyA tails derived from the Methanococcus jannaschii
genome were added to each encoded fraction at 100pg per mRNA
such that each fraction contained 4-to-6 control mRNAs
recognized by 16-to-24 unique probes on the MEEBO DNA
microarray (sequences, and PCR primers provided in Table S5).
15 fractions were separated into two pools, A and B, as per Table
S6, and the RNA was harvested as per the invitrogen Purelink
Micro-to-Midi (since replaced by the Mini cat.# 12183018A)
RNA purification kit for liquid samples with the exception that the
lysis buffer:lysate:EtOH were in a 1:1:2 stoichiometry before
loading onto the column. 1 ug of purified RNA was amplified
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cat.# AM1753) and labeled with Cy5 for pool A and Cy3 for pool
B. See ‘‘Scanning and Data Processing’’ for assignment of oligos to
average ribosome number.
DNA Microarray Production and Prehybridization
Processing
MEEBO oligonucleotide microarrays were printed on epox-
ysilane-coated glass (Schott Nexterion E) by the Stanford
Functional Genomic Facility. The MEEBO microarrays contain
,39,000 70-mer oligonucleotide probes, representing ,30,000
unique genes. A detailed description of this probe set can be found
at http://www.microarray.org/sfgf/meebo.do. Prior to hybridiza-
tion, slides were first incubated in a humidity chamber (Sigma
Cat# H6644) containing 0.56 SSC (16 SSC =150 mM NaCl,
15 mM sodium citrate [pH 7.0]) for 30 min at room temperature.
Slides were snap-dried at 70–80uC on an inverted heat block. The
free epoxysilane groups were blocked by incubation with 1 M
Tris-HCl (pH 9.0), 100 mM ethanolamine, and 0.1% SDS for
20 min at 50uC. Slides were washed twice for 1 min each with
400 ml of water, and then dried by centrifugation. Slides were
used the same day.
DNA Microarray Sample Preparation, Hybridization, and
Washing
Amplified RNA was used for all DNA microarray experiments.
Poly-adenylated RNAs were amplified in the presence of
aminoallyl-UTP with Amino Allyl MessageAmp II aRNA kit
(Ambion Cat# 1753). For mRNA expression experiments,
universal mouse reference RNA was used as an internal standard
to enable reliable comparison of relative transcript levels in
multiple samples (Stratagene cat.# 750600). Amplified RNA (5–
10 mg) was fluorescently labeled with NHS-monoester Cy5 or Cy3
(GE HealthSciences Cat# RPN5661). Dye-labeled RNA was
fragmented (Ambion Cat# 8740), then diluted into in a 50-ml
solution containing 36 SSC, 25 mM Hepes-NaOH (pH 7.0),
20 mg of human Cot-1 DNA (Invitrogen Cat# 15279011), 20 mg
of poly(A) RNA (Sigma Cat# P9403), 25 mg of yeast tRNA
(Invitrogen Cat# 15401029), and 0.3% SDS. The sample was
incubated at 70uC for 5 min, spun at 14,000 rpm for 10 min in
a microcentrifuge, then hybridized at 65uC using the MAUI
hybridization system (BioMicro) for 12–16 h.
For gradient encoding experiments, each fraction was divided
into two pools, ‘‘A’’ and ‘‘B’’ according to Table S6. Amplified
RNA from pools A was fluorescently labeled with NHS-monoester
Cy5, and RNA from pools B was fluorescently labeled with NHS-
monoester Cy3. Amplified RNA from pools A and B were
comparatively hybridized to a DNA microarray to obtain each
mRNA’s average sedimentation within the gradient.
Following hybridization, microarrays were washed in a series of
four solutions containing 400 ml of 26 SSC with 0.05% SDS,
20058 SSC, 16SSC, and 0.26SSC, respectively. The first wash
was performed for 5 min at 65uC. The subsequent washes were
performed at room temperature for 2 min each. Following the last
wash, the microarrays were dried by centrifugation in a low-ozone
environment (,5 ppb) to prevent destruction of Cy dyes. Once
dry, the microarrays were kept in a low-ozone environment during
storage and scanning (see http://cmgm.stanford.edu/pbrown/
protocols/index.html).
Scanning and Data Processing
Scanning and Data Processing were performed as previously
described [29] with the following exceptions. Data were filtered to
exclude elements that did not have one of the following:
a regression correlation of $0.6 between Cy5 and Cy3 signal
over the pixels comprising the array element, or an intensity/
background ratio of $2.5 in at least one channel. For mRNA
abundance measurements, red/green ratios were normalized by
linear regression to the line fitting the red/green ratios for a set of
doping controls (Ambion cat.# AM1780)) doped at various
relative concentrations into the total lysate and reference samples
for each array (see Table S7 for ratios of Ambion doping controls).
The red/green ratio for the encoded samples were related to
ribosome number as previously described [29], and as described
briefly below. Log2(red/green) ratios from the oligos representing
the in vitro transcribed doping controls were normalized by linear
regression to the expected ratios of doping controls from each
fraction, allowing empirical red/green ratios to be expressed as
a function of fraction number. The mid-point of each fraction was
expressed in terms of time and related to the Log of the mid point
of each A260 peak expressed in time – allowing fraction number to
be expressed in terms of ribosome peaks, and thus red/green ratios
to be related to average ribosome numbers.
The Pearson correlations of the log of the average ribosome
numberbetweenreplicateexperimentswere.0.95foralluntreated
and imatinib-treated replicates, and 0.89 to 0.96 for rapamycin
replicates.ForSAM,unpairedtwo-classt-testswereperformedwith
defaultsettingswithmeancenteringappliedtoallarrays(R-package
samr; http://cran.r-project.org/web/packages/samr/index.html).
Onlynon-controlmicroarrayfeaturesthatpassedqualityfilteringin
all replicates were used in the analyses. GO term and KEGG
pathway analysis was performed using Gene Trail software [101],
whichcanbefoundathttp://genetrail.bioinf.uni-sb.de/using over-
representation analysis withthe set of allgenes for whichtranslation
data were acquired as reference. Settings were all default using the
FDR adjustment for multiple testing. The data discussed in this
publication have been deposited in NCBI’s Gene Expression
Omnibus [102] and are accessible through GEO Series accession
number GSE35051 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE35051).
Proteomics Data Acquisition and Analysis
Imatinib treatment was performed as specified in ‘‘Cell Lines
and Cell Culture’’. Cells were harvested by resuspension in RIPA
buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1%
sodium deoxycholate, 0.1% SDS), immediately boiled in sample
buffer. Lysate from an equal number of medium-labeled, imatinib-
treated cells and heavy-labeled, untreated cells (corresponding to
roughly 30 mg of each lysate) were run on 4–12% Bis-Tris
polyacrylamide gels (BioRad, cat.# 345-0124). The same pro-
cedure was carried out for the reverse combination of lysates from
heavy-labeled, imatinib-treated and medium-labeled, untreated
cells. Each of the two lanes was cut into 8 slices that were
interrogated using high-resolution tandem MS using an LTQ
OrbiTrap XL mass spectrometer (Thermo-Finnigan) coupled with
a nanoLC 2D, a two-dimensional HPLC system (Eksigent). The
spectra were acquired in a data-dependent mode in m/z range of
40021800, with selection of the five most abundant +2o r+3 ions
of each MS spectrum for MS/MS analysis. MS/MS spectra were
searched using X! Tandem [103] (2007.01.01) with an alternative
scoring plugin [104] compatible with PeptideProphet [103].
Searches were conducted against the mouse International Protein
Index database (IPI Mouse v3.79) plus common contaminants. All
searches used the following parameters: 62.5 Da precursor mass
error, tryptic cleavage with up to one missed cleavage site, static
modifications of 57.021 Da (iodoacetamide) on cysteine and
6.0201 Da (medium label) on arginine, potential modifications of 4
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15.9949 Da (oxidation) on methionine. Peptide assignments given
an identification probability less than 0.95 by PeptideProphet were
removed. For each remaining peptide identification, we de-
termined the ratio of medium to heavy isotope, which should
reflect the change in production of the corresponding protein after
12 hours of imatinib treatment, using the XPress quantitation
algorithm [105]. The quality of the peptide ratio data was ensured
as follows: low-quality peptide quantitative ratios were algorith-
mically identified and removed from the dataset using the
previously-described Qurate software tool [106]; all remaining
ratios representing a peptide abundance change greater than 1.5-
fold in either direction were visually examined using Qurate, and
low-quality events were removed; finally, all remaining log-ratios
were median-centered on zero to eliminate sample loading bias.
Protein inference was performed using ProteinProphet [107].
Since only high-quality peptide identifications were used for
protein inference, only proteins with ProteinProphet probability
,0.05 were rejected outright. Protein identifications were further
restricted to proteins for which at least two unique peptide
sequences were identified. Protein quantitative ratios were de-
termined using the geometric mean of all assigned peptide ratios,
and the data from both the ‘‘forward’’ and ‘‘reverse’’ experiments
were combined (with ‘‘reverse’’ ratios flipped so that all ratios were
expressed as treated:untreated) to determine the geometric mean
ratios of imatinib-treated/untreated peptides. For comparison to
the pSILAC data, translation and mRNA abundance values for
multiple oligos representing one gene were averaged (see Table
S1).
Traditional Polysome Profiling
Lysates and sucrose gradients were prepared as in ‘‘Translation
Profiling’’ with half the volume (225 uL) collected per fraction.
,30 pg of a poly-adenylated M. jannaschii doping control RNA
was added to each fraction prior to harvesting total RNA with the
Micro-to-Midi (since replaced by the Mini cat.# 12183018A)
RNA isolation kit. An equal volume of RNA (roughly ,1/3 of the
fraction) was reverse-transcribed using Superscript III (Invitrogen,
cat.#18080-044) with an oligo(dT)12-18 primer (Invitrogen,
cat.#18418-12) from each of the fractions. cDNA from each
fraction was treated with 1.2 units of RNaseH for 30 minutes at
37uC. Quantitative PCR was performed on 3 mL of cDNA (after
diluting them from 1:5 up to 1:60 depending on the estimated
abundance of the transcript) with inventoried taqman primer and
probe sets from Applied Biosystems (see Table S8) using an
HT7900 Sequence Detector (ABI). Primer probe sets for taqman
for the MJ in vitro transcribed RNA are in Table S8. The standard
consisted of ten-fold serial dilutions of cDNA made as above from
5 mg of imatinib- treated and untreated total cytoplasmic lysate
RNA with 10 pg of control RNA added.
PCR was performed in triplicate on samples, controls and
standards; the mean values were divided by the mean values for
the doping control reactions with appropriate propagation of
error. The values were further normalized such that the sum of the
normalized qRT-PCR values for each gradient equaled 1.
The relative abundance of transcripts between treated and
untreated samples was calculated by comparing the values of three
serial dilutions of untreated to the treated samples. All PCR assays
had an R
2 value of .0.99 for the linear regression of the standards
and all values were within the linear range for each assay.
Explicit Calculation of ‘‘Encoding’’ Values from the qRT-
PCR Results
In order to quantitatively validate the encoding method we
explicitly ‘‘encoded’’ the values obtained by qRT-PCR for
individual fractions using a set of 9 genes with varying SAM
scores and local FDR predictions. The mean normalized qRT-
PCR value for each fraction was multiplied by the percentage of
each fraction that would have been labeled by Cy3 in the encoding
experiment. The same analysis was performed for Cy5 for each
fraction. The theoretical amounts of Cy3 and Cy5 for each
transcript were summed, and the theoretical Cy5/Cy3 ratio for
each transcript was calculated. The Cy5/Cy3 ratios were
expressed in terms of fractions using the slope and intercept
obtained by linear regression of the expected Cy5/Cy3 ratio for
each fraction. In order to control for the fact that not all gradients
(and the fractions taken therein) are perfectly super-imposable, we
expressed the fractions from each gradient in terms of ribosome
peaks using the same ‘‘peak finding’’ function in R used for the
encoding. As with Gradient Encoding, the Log2 ratio of the
treated to untreated average ribosome number was calculated.
Log2 (treated/untreatead) values for genes represented by two
oligo probes for the Gradient Encoding were averaged.
Supporting Information
Figure S1 qRT-PCR was performed on fractions from
high-resolution sucrose gradients on lysates from cells
either un-treated (in light blue) or treated with imatinib
(in pink). A) qRT-PCR was performed on an equal portion of
RNA harvested from each fraction from the sucrose gradient using
ABI inventoried taqman assays for qRT-PCR (see Fig. 2 for the
remaining two genes). Values were normalized by those for
a doping control RNA added to each fraction prior to harvesting
the RNA. The y-axis represents relative absorbance across each
gradient (Arbitrary Units, AU). B) The ratio of mRNA abundance
in cytoplasmic lysates before and after imatinib treatment was
measured in the same experiment using the same taqman probes
and primer sets. The untreated samples were normalized to 1 for
each individual probe and primer set.
(PDF)
Figure S2 pSILAC data represents an unbiased set of
genes. The scatterplot of Log2 (imatinib-treated/untreated)
values for translation vs. mRNA abundance is shown with oligos
representing genes represented in the pSILAC data in red.
(PDF)
Figure S3 Heatmaps of genes in the enriched GO term
categories representing the average change upon treat-
ment. A) Average change in translation (expressed in standard
deviations) upon either imatinib- or rapamycin-treatment is
depicted from top to bottom in order of increasing change in
translation upon rapamycin treatment for the following categories:
Translation, Mitochondrial Part (Mitochondria), Antigen Proces-
sing, Lysosome, Proteasome, Nucleus, phosphatidylinositol (PI)
signaling and regulation of actin cytoskeleton (Actin cytoskeleton).
B) The same as A but the change in translation is compared to the
change in mRNA abundance upon imatinib treatment in order of
increasing change in mRNA abundance. In cases where multiple
oligos represent a gene, the oligo with the biggest change in
translation upon imatinib treatment was used. Genes that passed
the 10% FDR cutoff for translation upon imatinib treatment, but
not upon rapamycin treatment (A) or for change in mRNA
abundance upon imatinib treatment (B) are highlighted in yellow.
(PDF)
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ent Encoding, and mRNA abundance data. Gradient
Encoding and mRNA abundance data for multiple oligos
representing the same gene were averaged. All values are given
as Log2 (treated/untreated) and are sorted in ascending order for
pSILAC value.
(XLS)
Table S2 Genes translationally activated by imatinib.
Genes are listed in order of SAM score starting with the most
significantly imatinib-regulated gene. Values are given for in-
dividual oligos on the array, therefore some genes are represented
more than once. Genes with multiple oligos for which the standard
deviation between the oligos was more than half the average
difference from the mean were assigned footnotes to categorize the
nature of the discrepancy between oligos (ie. plausibly due to splice
variation, or alternative polyadenylation, etc.). Those genes with
discordant oligos that could not be explained by the above criteria
(footnote 4) were removed from the bioinformatic functional
analyses. The columns indicate the following from left to right:
Gene symbol from master dataset, alternate names where
MEEBO master dataset gene symbols are absent or possibly
misleading, footnote corresponding to the nature of the discrep-
ancy in cases where multiple oligos representing one gene are
discordant, accession number, description of the protein product,
the Log2 ratio of average ribosome number of imatinib-treated to
untreated lysate, SAM score, FDR (%), the same for changes in
mRNA abundance (Log ratio, SAM, FDR (%)), changes in
average ribosome number upon rapamycin treatment (Log ratio,
SAM, FDR (%)), and rapamycin-induced changes in mRNA
abundance (Log ratio, SAM, FDR (%)), sequence of the oligo
probe on the array.
(XLS)
Table S3 Genes translationally repressed by imatinib
in increasing order by SAM score. Column headings are as
in Table S2.
(XLS)
Table S4 Genes representing the GO term and KEGG
pathway enrichments are listed grouped by GO term or
KEGG pathway, and subsequently ordered in ascending
SAM score of the translational response to imatinib.
Genes belonging to more than one category are listed in each
category. Columns as in Table S2.
(XLS)
Table S5 MJ in vitro transcribed RNA sequences, and
PCR primers used to amplify them.
(XLS)
Table S6 Pooling of fractions for gradient encoding.
(XLS)
Table S7 Ratios of Ambion doping controls used to
normalize the mRNA abundance data.
(XLS)
Table S8 Taqman probes used for qRT-PCR analysis.
(XLS)
Data S1 Master datasheet for all non-control oligos.
Translation change, Abundance change, and pSILAC change are
all expressed as Log2 (treated/untreated). ‘‘Probe’’ denotes the
sequence of the oligo on the MEEBO array to which the data
correspond. (Imat. = imatinib, Abund. = abundance, Rap. =
rapamycin)
(TXT)
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